Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Multiple Myeloma: Treatment is Getting Individualized.

Agarwal MB.

Indian J Hematol Blood Transfus. 2016 Mar;32(1):3-9. doi: 10.1007/s12288-015-0575-5. Epub 2015 Jul 26. Review.

PMID:
26855501
2.

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.

Cornell RF, Kassim AA.

Bone Marrow Transplant. 2016 Apr;51(4):479-91. doi: 10.1038/bmt.2015.307. Epub 2016 Jan 4. Review.

3.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

4.

Interpretation of cytogenetic results in multiple myeloma for clinical practice.

Rajan AM, Rajkumar SV.

Blood Cancer J. 2015 Oct 30;5:e365. doi: 10.1038/bcj.2015.92. Review.

5.

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A.

Blood Cancer J. 2015 Aug 14;5:e338. doi: 10.1038/bcj.2015.60.

6.

MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S.

Integr Biol (Camb). 2015 Jun;7(6):643-54. doi: 10.1039/c5ib00071h. Epub 2015 May 22.

7.

Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapy.

Zeng T, Zhou L, Xi H, Fu W, Du J, Zhang C, Jiang H, Hou J.

Stem Cells Int. 2015;2015:613045. doi: 10.1155/2015/613045. Epub 2015 Jan 22.

8.

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.

Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK.

Br J Haematol. 2015 Apr;169(2):219-27. doi: 10.1111/bjh.13296. Epub 2015 Feb 13.

9.

The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.

Prideaux SM, Conway O'Brien E, Chevassut TJ.

Bone Marrow Res. 2014;2014:526568. doi: 10.1155/2014/526568. Epub 2014 Sep 11.

10.

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R.

Blood. 2014 Aug 14;124(7):1047-55. doi: 10.1182/blood-2014-01-548941. Epub 2014 Jun 5.

11.

Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.

Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH.

Leuk Lymphoma. 2015 Mar;56(3):602-7. doi: 10.3109/10428194.2014.924116. Epub 2014 Aug 18.

12.

The morphology of myeloma cells changes with progression of the disease.

Wajs J, Sawicki W.

Contemp Oncol (Pozn). 2013;17(3):272-5. doi: 10.5114/wo.2013.35282. Epub 2013 Jun 28.

13.

Current approaches to the initial treatment of symptomatic multiple myeloma.

Jasielec JK, Jakubowiak AJ.

Int J Hematol Oncol. 2013 Feb;2(1). doi: 10.2217/ijh.13.3.

14.

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E.

Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430.

15.

Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.

Kumar SK, Mikhael J, Laplant B, Lacy MQ, Buadi FK, Dingli D, Gertz MA, Laumann K, Miceli T, Mahlman M, Bergsagel LP, Hayman SR, Reeder C, Stewart AK, Dispenzieri A, Gastineau DA, Winters JL.

Bone Marrow Transplant. 2014 Feb;49(2):201-5. doi: 10.1038/bmt.2013.175. Epub 2013 Nov 4.

16.

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.

Greenberg AJ, Rajkumar SV, Therneau TM, Singh PP, Dispenzieri A, Kumar SK.

Leukemia. 2014 Feb;28(2):398-403. doi: 10.1038/leu.2013.258. Epub 2013 Sep 5.

17.

Implications of continued response after autologous stem cell transplantation for multiple myeloma.

Gonsalves WI, Gertz MA, Dispenzieri A, Lacy MQ, Lin Y, Singh PP, Gupta V, Hayman SR, Buadi FK, Dingli D, Kapoor P, McCurdy AR, Kumar SK.

Blood. 2013 Sep 5;122(10):1746-9. doi: 10.1182/blood-2013-03-492678. Epub 2013 Jul 17.

18.

Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.

Jekarl DW, Min CK, Kwon A, Kim H, Chae H, Kim M, Lim J, Kim Y, Han K.

Ann Lab Med. 2013 Jul;33(4):248-54. doi: 10.3343/alm.2013.33.4.248. Epub 2013 Jun 24.

19.

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.

Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1227-32. doi: 10.1016/j.bbmt.2013.05.017. Epub 2013 May 31.

20.

Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.

Greenberg AJ, Cousin M, Kumar S, Ketterling RP, Knudson RA, Larson D, Colby C, Scott C, Vachon CM, Rajkumar SV.

Eur J Haematol. 2013 Sep;91(3):193-5. doi: 10.1111/ejh.12133. Epub 2013 Jul 22.

Items per page

Supplemental Content

Write to the Help Desk